Intriguingly, a difference in the outcomes of patients with MYB and MYBL1 alterations has been recently revealed, with the former group showing a significantly shorter survival [6], although studies conducted in larger cohorts of ACC patients are essential to delineate clinical impact of this finding. Here, MYB is linked to adrenal cortex carcinoma.